Ray:
Message 13555232
>> MLNM, VRTX, NBIX, NRGN, MAXM, VPHM, NBSC, BTRN, SEPR, VIRS, ITMN, and NPSP. <<
Since 5/3, this list has performed well. BTRN got clobbered as Rosenwald bailed, but it's come back with some strength.
However, there are also four non-movers or relative non-movers...... NRGN, VPHM, NBSC, and VIRS. None of them are additions to (or deletions from) Russell.
Very different creatures......
NRGN.... nobody sees any major movers on horizon, but company is loaded with drug discovery tech and is often mentioned as an acquisition target.
VPHM.... massive selling. It has to end sometime, correct? Correct? PLEASE tell me I'm correct! Cash in the bank is a "loan", but it's equal to the current capitalization. Bad news from "common cold" drug, but valuation is barely above cash in bank and there are very good projects for HCV and RSV. The first HCV candidate is oral-active and is in phase I clinical trial. Partner is Wyeth-Ayerst. The RSV molecule is potent, but delivery may be a problem. They signed up Battelle, early, for exploring pulmonary. Decent sized short position.
NBSC..... Roach Motel. No liquidity. To me (everyone should get their own opinion), downside risk looks minimal. Well situated for low-tech trickle down from genomics, as they manufacture and sell the very basics of the laboratory.... shakers, incubators, rollers, ultralow freezers, etc. Also own 80% of a biotech that has (issued) an extremely broad patent claim and a collaboration with Novo Nordisk.
VIRS..... bad news from South Africa. Lots of room for good news, some room for more bad news. Seems a bit volatile with an upside bias of late. HIV and HBV, respected in both.
Sure is nice to have this thread back. As always, would appreciate your opinions, good or bad.
Rick |
